Kanilad

Lacosamide, the active ingredient in Kanilad, is a sodium channel blocker presented as an oral tablet for oral use. It is used as adjunctive therapy for partial‑onset seizures in patients with epilepsy. GNH USA supplies Kanilad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kanilad, a sodium channel blocker, is employed in the management of seizure disorders. - Partial‑onset seizures: Reduces seizure frequency when added to existing antiepileptic regimens. - Focal epilepsy: Helps achieve better overall seizure control in patients with focal seizure types. - Epilepsy (adjunctive therapy): Contributes to improved seizure management as part of a comprehensive treatment plan.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: A sensation of light‑headedness or unsteadiness. - Headache: Mild to moderate pain in the head region. - Nausea: Feeling of stomach upset or urge to vomit. - Fatigue: Unusual tiredness or lack of energy. - Blurred vision: Temporary visual disturbances. - Diplopia: Double vision.

Serious or Rare Side Effects: - Suicidal thoughts or behavior: Emergence of depressive symptoms or suicidal ideation. - Severe skin reactions: Including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: Irregular heart rhythms, especially in patients with pre‑existing conduction disorders. - Respiratory depression: Marked slowing of breathing. - Anaphylaxis: Acute allergic reaction with potential airway compromise. - Liver injury: Elevated liver enzymes or hepatitis.

When prescribing or dispensing Kanilad, consider the following safety measures. - Renal impairment: Assess kidney function and adjust therapy if necessary. - Hepatic impairment: Monitor liver enzymes regularly. - Concomitant antiepileptics: Observe for increased central nervous system side effects. - Cardiac conduction disorders: Use with caution in patients with known arrhythmias. - Pregnancy: Potential risks are unknown; discuss benefits and risks with a healthcare professional. - Store at room temperature: Keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): May lower lacosamide plasma levels. - Other sodium channel blockers (e.g., lamotrigine, phenytoin): May increase neurotoxicity. - QT‑prolonging agents (e.g., quinidine, erythromycin): Heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Oral contraceptives: May reduce contraceptive effectiveness; consider alternative methods. - Combination with other antiepileptics: May increase dizziness or somnolence. - Alcohol: Can enhance central nervous system depression and impair coordination.